Search

Your search keyword '"Sørensen, I. J."' showing total 47 results

Search Constraints

Start Over You searched for: Author "Sørensen, I. J." Remove constraint Author: "Sørensen, I. J."
47 results on '"Sørensen, I. J."'

Search Results

1. AB0976 PLASMA PROTEIN INTER-ALPHA-TRYPSIN INHIBITOR HEAVY CHAIN 4 (ITIH4) LEVELS IN PATIENTS WITH axSpA AND RESPONSE TO TNF-INHIBITOR THERAPY

3. POS0298 OCCURRENCE AND PREDICTION OF FLARE AFTER TAPERING OF TNF INHIBITORS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS

7. POS0955 EXTRACELLULAR MATRIX PROTEIN TURNOVER MARKERS ARE ASSOCIATED WITH axSpA – A COMPARISON WITH CONTROL SUBJECTS WITH OR WITHOUT PELVIC, BUTTOCK OR BACK PAIN

9. Scoring magnetic resonance imaging (MRI) inflammation and structural lesions in sacroiliac joints of patients with axial spondyloarthritis:assessment of all MRI slices of the cartilaginous compartment versus standardized six or five slices

12. SAT0548 DEVELOPMENT AND VALIDATION OF THREE PRELIMINARY MRI SACROILIAC JOINT COMPOSITE STRUCTURAL DAMAGE SCORES IN A 5-YEAR LONGITUDINAL STUDY OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS

14. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection

15. Comparing patient-reported outcomes entered at home versus at hospital, and testing touch screens for initial recruitment to scientific trials in arthritis patients

16. Structural progression rate decreases over time on serial radiography and magnetic resonance imaging of sacroiliac joints and spine in a five-year follow-up study of patients with ankylosing spondylitis treated with tumour necrosis factor inhibitor

17. One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the DANBIO registry

19. Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care

20. Scoring magnetic resonance imaging (MRI) inflammation and structural lesions in sacroiliac joints of patients with axial spondyloarthritis: assessment of all MRI slices of the cartilaginous compartment versus standardized six or five slices.

22. Comparing patient-reported outcomes entered at home versus at hospital, and testing touch screens for initial recruitment to scientific trials in arthritis patients.

23. Structural progression rate decreases over time on serial radiography and magnetic resonance imaging of sacroiliac joints and spine in a five-year follow-up study of patients with ankylosing spondylitis treated with tumour necrosis factor inhibitor.

24. Non-medical switch from originator to biosimilar in fliximab in patients with inflammatory arthritis:impact on s-infliximab and antidrug antibodies. Results from the Danish Rheumatological Biobank and the DANBIO registry

25. Three months’ clinical outcomes from a nationwide non-medical switch from originator to biosimilar infliximab in patients with in flammatory arthritis:Results from the DANBIO registry

26. Responsiveness of A New MRI Scoring Method Based on The Canada-Denmark Definitions of Lesions in The Spine and The SPARCC MRI Spine Inflammation Index in Patients with Axial Spondyloarthritis

27. Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease:Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry

28. The Anatomical Distribution of Inflammation, Fat, Erosion and New Bone Formation in The Spine Assessed According To The Canada-Denmark MRI Definitions in Patients with Axial Spondyloarthritis

29. Three Months' Clinical Outcomes from A Nationwide Non-Medical Switch from Originator To Biosimilar Infliximab in Patients with Inflammatory Arthritis:Results from The Danbio Registry

31. Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care.

32. Pattern of bone erosion and bone proliferation in psoriatic arthritis hands:a high-resolution computed tomography and radiography follow-up study during adalimumab therapy

33. Serum electrolytes and drug therapy of patients admitted to a geriatric department

34. Native Human Serum Amyloid P Component is a Single Pentamer.

35. One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the DANBIO registry

36. One-year follow-up of a nationwide cohort of patients with inflammatory arthritis, who switched from originator to biosimilar etanercept, focusing on patients who switched back to originator. an observational danbio study

37. Pattern of bone erosion and bone proliferation in psoriatic arthritis hands: a high-resolution computed tomography and radiography follow-up study during adalimumab therapy.

38. Re-activation of bovine tuberculosis in a patient treated with infliximab.

39. Complexes of serum amyloid P component and DNA in serum from healthy individuals and systemic lupus erythematosus patients.

40. [Dengue fever].

41. Calcium-dependent and -independent binding of the pentraxin serum amyloid P component to glycosaminoglycans and amyloid proteins: enhanced binding at slightly acid pH.

42. Binding of complement proteins C1q and C4bp to serum amyloid P component (SAP) in solid contra liquid phase.

43. Multiple isoforms of the human pentraxin serum amyloid P component.

44. Calcium-enhanced aggregation of serum amyloid P component and its inhibition by the ligands heparin and heparan sulphate. An electron microscopic and immunoelectrophoretic study.

45. [Serum electrolytes and drug therapy of patients admitted to a geriatric department].

46. Family studies of complement C4 and HLA in man.

47. Genetic studies of complement C4 in man.

Catalog

Books, media, physical & digital resources